1
|
Allchin RL, Wickenden K, Pilgrim S, Wilson-Morkeh I, Miall FM. The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL. Hemasphere 2020; 4:e501. [PMID: 33283170 PMCID: PMC7710186 DOI: 10.1097/hs9.0000000000000501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2020] [Accepted: 10/13/2020] [Indexed: 11/25/2022] Open
Affiliation(s)
- Rebecca L Allchin
- Department of Hematology, University Hospitals, Leicester, United Kingdom
| | | | - Simon Pilgrim
- Department of Breast Surgery, University Hospitals, Leicester, United Kingdom
| | - Issac Wilson-Morkeh
- Department of Hematology, Kettering General Hospital, Kettering, United Kingdom
| | - Fiona M Miall
- Department of Hematology, University Hospitals, Leicester, United Kingdom
| |
Collapse
|
2
|
Allchin RL, Kelly ME, Mamand S, Doran AG, Keane T, Ahearne MJ, Wagner SD. Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma. PLoS One 2019; 14:e0215765. [PMID: 31013298 PMCID: PMC6478326 DOI: 10.1371/journal.pone.0215765] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Accepted: 04/07/2019] [Indexed: 01/22/2023] Open
Abstract
Recent analyses of the genetics of peripheral T-cell lymphoma (PTCL) have shown that a large proportion of cases are derived from normal follicular helper (Tfh) T-cells. The sanroque mouse strain bears a mutation that increases Tfh cell number and heterozygous animals (Roquinsan/+) develop lymphomas similar to human Tfh lymphoma. Here we demonstrate the usefulness of Roquinsan/+ animals as a pre-clinical model of Tfh lymphoma. Long latency of development and incomplete penetrance in this strain suggests the lymphomas are genetically diverse. We carried out preliminary genetic characterisation by whole exome sequencing and detected tumor specific mutations in Hsp90ab1, Ccnb3 and RhoA. Interleukin-2-inducible kinase (ITK) is expressed in Tfh lymphoma and is a potential therapeutic agent. A preclinical study of ibrutinib, a small molecule inhibitor of mouse and human ITK, in established lymphoma was carried out and showed lymphoma regression in 8/12 (67%) mice. Using T2-weighted MRI to assess lymph node volume and diffusion weighted MRI scanning as a measure of function, we showed that treatment increased mean apparent diffusion coefficient (ADC) suggesting cell death, and that change in ADC following treatment correlated with change in lymphoma volume. We suggest that heterozygous sanroque mice are a useful model of Tfh cell derived lymphomas in an immunocompetent animal.
Collapse
MESH Headings
- Adenine/analogs & derivatives
- Administration, Oral
- Animals
- Antineoplastic Agents/administration & dosage
- Disease Models, Animal
- Drug Evaluation, Preclinical/methods
- Heterozygote
- Humans
- Lymph Nodes/cytology
- Lymph Nodes/diagnostic imaging
- Lymph Nodes/drug effects
- Lymphoma, T-Cell, Peripheral/diagnostic imaging
- Lymphoma, T-Cell, Peripheral/drug therapy
- Lymphoma, T-Cell, Peripheral/genetics
- Magnetic Resonance Imaging
- Mice
- Piperidines
- Primary Cell Culture
- Pyrazoles/administration & dosage
- Pyrimidines/administration & dosage
- T-Lymphocytes, Helper-Inducer/drug effects
- T-Lymphocytes, Helper-Inducer/pathology
- Treatment Outcome
- Tumor Cells, Cultured
- Ubiquitin-Protein Ligases/genetics
Collapse
Affiliation(s)
- Rebecca L. Allchin
- Leicester Cancer Research Centre and Ernest and Helen Scott Haematology Research Institute, University of Leicester, Leicester, United Kingdom
| | - Michael E. Kelly
- Core Biotechnology Services, University of Leicester, Leicester, United Kingdom
| | - Sami Mamand
- Leicester Cancer Research Centre and Ernest and Helen Scott Haematology Research Institute, University of Leicester, Leicester, United Kingdom
| | - Anthony G. Doran
- European Bioinformatics Institute, Hinxton, Cambridge, United Kingdom
| | - Thomas Keane
- European Bioinformatics Institute, Hinxton, Cambridge, United Kingdom
| | - Matthew J. Ahearne
- Leicester Cancer Research Centre and Ernest and Helen Scott Haematology Research Institute, University of Leicester, Leicester, United Kingdom
| | - Simon D. Wagner
- Leicester Cancer Research Centre and Ernest and Helen Scott Haematology Research Institute, University of Leicester, Leicester, United Kingdom
- * E-mail:
| |
Collapse
|
3
|
Ladikou E, Ottolini B, Nawaz N, Allchin RL, Payne D, Ali H, Marafioti T, Shaw J, Ahearne MJ, Wagner SD. Clonal evolution in the transition from cutaneous disease to acute leukemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm. Haematologica 2018; 103:e196-e199. [PMID: 29419438 DOI: 10.3324/haematol.2017.171876] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Affiliation(s)
- Eleni Ladikou
- Leicester Cancer Research Centre, University of Leicester, UK.,Ernest and Helen Scott Haematology Research Institute, University of Leicester, UK
| | - Barbara Ottolini
- Leicester Cancer Research Centre, University of Leicester, UK.,Ernest and Helen Scott Haematology Research Institute, University of Leicester, UK
| | - Nadia Nawaz
- Leicester Cancer Research Centre, University of Leicester, UK.,Ernest and Helen Scott Haematology Research Institute, University of Leicester, UK
| | - Rebecca L Allchin
- Leicester Cancer Research Centre, University of Leicester, UK.,Ernest and Helen Scott Haematology Research Institute, University of Leicester, UK
| | - Daniel Payne
- Department of Haematology, Leicester Royal Infirmary, UK
| | - Hebah Ali
- Department of Cellular Pathology, University College London Hospitals, UK
| | - Teresa Marafioti
- Department of Cellular Pathology, University College London Hospitals, UK
| | - Jacqui Shaw
- Leicester Cancer Research Centre, University of Leicester, UK
| | - Matthew J Ahearne
- Leicester Cancer Research Centre, University of Leicester, UK .,Ernest and Helen Scott Haematology Research Institute, University of Leicester, UK
| | - Simon D Wagner
- Leicester Cancer Research Centre, University of Leicester, UK .,Ernest and Helen Scott Haematology Research Institute, University of Leicester, UK
| |
Collapse
|
4
|
Beck D, Zobel J, Barber R, Evans S, Lezina L, Allchin RL, Blades M, Elliott R, Lord CJ, Ashworth A, Porter ACG, Wagner SD. Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma. J Biol Chem 2016; 291:16686-98. [PMID: 27268052 PMCID: PMC4974382 DOI: 10.1074/jbc.m116.736868] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 06/05/2016] [Indexed: 11/06/2022] Open
Abstract
We demonstrate the usefulness of synthetic lethal screening of a conditionally BCL6-deficient Burkitt lymphoma cell line, DG75-AB7, with a library of small molecules to determine survival pathways suppressed by BCL6 and suggest mechanism-based treatments for lymphoma. Lestaurtinib, a JAK2 inhibitor and one of the hits from the screen, repressed survival of BCL6-deficient cells in vitro and reduced growth and proliferation of xenografts in vivo BCL6 deficiency in DG75-AB7 induced JAK2 mRNA and protein expression and STAT3 phosphorylation. Surface IL10RA was elevated by BCL6 deficiency, and blockade of IL10RA repressed STAT3 phosphorylation. Therefore, we define an IL10RA/JAK2/STAT3 pathway each component of which is repressed by BCL6. We also show for the first time that JAK2 is a direct BCL6 target gene; BCL6 bound to the JAK2 promoter in vitro and was enriched by ChIP-seq. The place of JAK2 inhibitors in the treatment of diffuse large B-cell lymphoma has not been defined; we suggest that JAK2 inhibitors might be most effective in poor prognosis ABC-DLBCL, which shows higher levels of IL10RA, JAK2, and STAT3 but lower levels of BCL6 than GC-DLBCL and might be usefully combined with novel approaches such as inhibition of IL10RA.
Collapse
Affiliation(s)
- Daniel Beck
- From the Department of Cancer Studies, Ernest and Helen Scott Haematology Research Institute, and
| | - Jenny Zobel
- Department of Haematology, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN
| | - Ruth Barber
- From the Department of Cancer Studies, Ernest and Helen Scott Haematology Research Institute, and Leicester Diagnostic and Drug Development (LD3) Centre, University of Leicester, Lancaster Road, Leicester LE1 7HB
| | - Sian Evans
- From the Department of Cancer Studies, Ernest and Helen Scott Haematology Research Institute, and
| | - Larissa Lezina
- From the Department of Cancer Studies, Ernest and Helen Scott Haematology Research Institute, and
| | - Rebecca L Allchin
- From the Department of Cancer Studies, Ernest and Helen Scott Haematology Research Institute, and
| | - Matthew Blades
- Bioinformatics and Biostatistics Analysis Support Hub (B/BASH), University of Leicester, Lancaster Road, Leicester LE1 9HN, and
| | - Richard Elliott
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, United Kingdom
| | - Christopher J Lord
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, United Kingdom
| | - Alan Ashworth
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, United Kingdom
| | - Andrew C G Porter
- Department of Haematology, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN
| | - Simon D Wagner
- From the Department of Cancer Studies, Ernest and Helen Scott Haematology Research Institute, and
| |
Collapse
|
5
|
Ahearne MJ, Allchin RL, Fox CP, Wagner SD. Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. Br J Haematol 2014; 166:326-35. [PMID: 24815671 DOI: 10.1111/bjh.12941] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Accepted: 04/07/2014] [Indexed: 01/02/2023]
Abstract
Follicular helper T-cells (Tfh cells) are a subset of CD4(+) T-cells that are essential for normal production of high affinity antibodies. Tfh cells characteristically produce IL21 and IL4 and show high expression of surface markers CXCR5, ICOS, PDCD1 (PD-1) and the chemokine CXCL13. In this review we will focus on the emerging links between Tfh cells and subtypes of T-cell non-Hodgkin lymphoma: angioimmunoblastic T-cell lymphoma (AITL) and ~20% of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) have surface marker features of Tfh cells and share a spectrum of genetic abnormalities. The recurrent genetic abnormalities associated with AITL include mutations in epigenetic modifiers such as TET2 and DNMT3A and the motility and adhesion gene, RHOA, is mutated in up to 70% of cases. ~20% of PTCL-NOS demonstrate RHOA mutations and have other characteristics suggesting an origin in Tfh cells. The recognition that specific genetic and surface markers are associated with malignant Tfh cells suggests that the next few years will bring major changes in diagnostic and treatment possibilities. For example, antibodies against IL21, PDCD1 and ICOS are already in clinical trials for autoimmune disease or other malignancies and antibodies against CXCL13 are in pre-clinical development.
Collapse
Affiliation(s)
- Matthew J Ahearne
- Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK; Ernest and Helen Scott Haematology Research Institute, University of Leicester, Leicester, UK
| | | | | | | |
Collapse
|